.png){kind=icon}
Translational Biomarker Solutions
Exploratory biomarker insights to guide your decision-making from discovery to the clinic
Flexible, fit-for-purpose biomarker support to propel your drug development.
通过翻译生物标志物战略加速您的进度
Access collaborative support with fit-for-purpose assay development and validation
Identify and access cutting-edge technologies and expertise
Translational biomarkers can play a critical role in helping you quickly assess biomarker feasibility to better understand how it can be utilized in a clinical environment. When it comes to analytical characterization, one size doesn’t fit all. You need a flexible approach that considers your phase of development and desired outcomes to provide the best support for the intended use of your data.
探索性生物标志物，而不是由具体规定指导，仍然利用强大的质量原则，专业知识和流程来提供高质量和可靠的数据。具有熟悉CAP / CLIA和GXP环境的可信赖的合作伙伴可以简化您的转型，并保留对您的测定和目标的关键洞察力。
Since 2009, the Translational Biomarker Solutions (TBS) team has been supporting assay development and validation needs in an exploratory – but, principled – environment. Expertise in cellular analysis and immunoassays can help you develop your strategy from concept to implementation to meet your critical goals for exploratory biomarkers.
专业支持
免疫测定/ LBA
- 超灵敏的
- 定制免疫原性测定
- 低样品体积，具有改进的检测
- Multiplexed and specialized platform assays
- 电化学发光
- 基于Microfluidics的ELISA
- Kit-based immune assays
- Immunoassay autoanalyzers
Cellular-based Analysis
- 血液，PBMC和组织的高参数免疫蛋白型
- In vitro Pharmacology
- Immunotoxicology for cytokine release
- Cellular Immunology
- Cell-Based Assays (including ADCCs, CDCs, Proliferation, Apoptosis and viability, etc.)
灵活和适合的生物标志物测试解决方案
从初始可行性和开发到先进的验证，测试和生产，我们提供推动您的决策的见解。我们的团队为历史（银行）样本，困难的矩阵类型或复杂的测定开发提供了独特的解决方案，在灵活的环境中提供了强大的探索，以指导生物标志物发现的新路径。随着您的临床生物标志物需求的发展，TBS团队可以帮助您无缝过渡到CAP / CLIA或GXP环境进行资格，方法验证和实施。
Extended reach with access to the optimal technologies
跨敏感和多路复用，基于套件和定制，低样本和基于单元的测定的综合了解，为您提供了一个经验丰富的合作伙伴，可以访问不同平台的工具箱。我们可以通过使用精密技术来支持您的生物标志物分析并推进您的发现，例如：
- Quanterix Simoa
- Meso Scale Discovery (MSD)
- Luminex
- Protein Simple ELLA
- Gyros
- ECLIA (Roche e601)
- 八满座子
- Cytoflex (Beckman Coulter 6-color)
- Miltenyi Automacs Pro
- Miltenyi Octo Dissociator
- BD Fortessa X-20 (18-Color)
- CTL免疫部门
A quality approach to biomarkers in a non-regulated environment
In parallel with Covance’s regulated lab work, the TBS team works under a set of standardized quality principles to ensure accuracy and quality for your exploratory objectives of the studies. This system is further verified by both internal and external QA audits, as well as proficiency testing, giving you confidence that the data produced meets the highest standard of quality.
Working with TBS, you get a set of reliable and reconstructable results that enables informed development decisions and a structured transition to the regulatory environment required to progress to your next milestone.
Next, meet the team that will work with you to help solve your translational biomarker challenges.
Erica L. Troksa，PHD
Associate Director, Translational Biomarker Solutions
Dr. Erica L. Troksa drives overall scientific performance and quality delivery of on-time services for the Translational Biomarker Solutions team. She leverages her16多年的经验development, optimization and execution of bioanalytical immunoassays. Dr. Troksa has leddevelopment and validation of novel immunoassays for multiple platforms.
Before joining Covance in March of 2013, she served as Field Scientist for EMD Millipore, training research scientists on proper techniques in multiplexing immunoassays,flow cytometry, protein quantitation and other technical applications.Troksa博士赢得了伊利诺伊大学芝加哥伊利诺伊大学的埃克斯·勒纳奖。她是关于各种议题的几个同行评审日刊文章的作者或共同作者。
Paul C. Trampont, PhD
Principal Scientist and Senior Lab Manager, Translational Biomarker Solutions, Covance
Paul C. Trampont博士导致了一支科学家和技术人员，负责开发基于细胞的测定以支持药物开发。他于2014年12月加入了Covance，带来了20多年的人类免疫学和肿瘤学研究的专业经验。在加入Covance之前，他曾担任弗吉尼亚大学血液学和肿瘤科助理教授。
Dr. Trampont was awarded a Covance Scientific Excellence grant in December 2018. He is the author and co-author of numerous peer-reviewed scientific journal articles and abstracts, and is frequently invited to speak at industry conferences on topics related to method validation.
Bhaskarjyoti Sarmah，Phd
高级科学家和经理，翻译生物标志物解决方案
Dr. Bhaskarjyoti Sarmah leads our team of scientists responsible for developing, validating and implementing soluble biomarker immunoassays and bioassays.He draws on more than 10 years of experience working in biomarker and target discovery research across multiple therapeutic areas, including cardio-metabolic, renal, autoimmune/inflammatory diseases, and immuno-oncology.
Dr. Sarmah is the author or co-author of more than two dozen journal articles, posters and presentations. Before joining Covance in January 2017, he served as a Research Scientist in Biotechnology Discovery Research for Eli Lilly & Co.
Chris W. Stamatkin, PhD
Staff Scientist, Lead-Immunoassay and Special Chemistry, Translational Biomarker Solutions
Chris W. Stamatkin博士用作员工科学家，并为免疫测定和特殊化学领先。他领导了负责开发基于细胞的测定的科学家和技术人员团队，以支持药物发展。他于2017年11月加入了Covance，拥有超过14年的实验室研究和药物开发经验。
Dr. Stamatkin previously served as an Assistant Research Professor in the Division of Hematology/Oncology at Indiana University School of Medicine as well as Assistant Director, Therapeutic Validation Core and Angio BioCore at Indiana University Simon Cancer Center. Stamatkin shares his experience as author and co-author of numerous peer-reviewed scientific journal articles, abstracts and presentations, and is a frequent speaker at industry conferences.
凯瑟琳(Katie) A. Masterson
Immunoassay Lead, Translational Biomarker Solutions
Masterson女士领导负责开发生物标志物免疫大同作用的科学家团队，并在测定平台和检测方式上咨询客户。她于2014年1月加入Covance，并带来了超过15年的实验室研究和开发经验。
她是南部中央临床微生物学联系的成员，是几个出版物和海报演示的共同作者。在加入Covance之前，她为印第安纳州卫生实验室的病毒学主管服务了八年。